Hospital
Lee Memorial Health System
Lee Memorial Health System was paid $11.06M by Medicaid between Jan 2018 and Oct 2024, across 224 billing codes. Its largest line is G0257, Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility — 15% of everything it billed.
33Billing provider infoLEE MEMORIAL HEALTH SYSTEM
FORT MYERS, FL 33912
FORT MYERS, FL 33912
33aNPI1982658407assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.06M
24GClaims491,374
24DCodes billed224
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#46 of 163
Median peer was paid$4.77M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SPENCE, BENJAMIN controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,558 | $705K | |
| 2019 | 89,767 | $1.47M | |
| 2020 | 82,845 | $1.50M | |
| 2021 | 118,872 | $2.58M | |
| 2022 | 119,681 | $3.37M | |
| 2023 | 36,074 | $1.32M | |
| 2024incomplete | 3,577 | $113K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 15% | 4,429 | 724 | $1.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 21,512 | 15,729 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 8,608 | 7,536 | $574K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.4% | 5,305 | 4,366 | $489K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 4.2% | 7,859 | 7,276 | $464K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.2% | 3,775 | 3,265 | $460K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 2,519 | 2,215 | $451K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.4% | 7,950 | 5,591 | $373K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 13,143 | 10,631 | $327K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 5,007 | 4,067 | $324K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 4,173 | 3,422 | $284K |
| G0378 | Hospital observation service, per hour | 2.4% | 8,655 | 4,240 | $270K |
212 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,075 | $269K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 2.0% | 3,507 | $221K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 5,920 | $202K |
| 99285 | Emergency room visit (most serious) | 1.8% | 2,936 | $199K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,322 | $171K |
| 80053 | Comprehensive metabolic panel | 1.5% | 35,129 | $167K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,565 | $131K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 2,335 | $128K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 7,218 | $127K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.1% | 2,375 | $118K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,219 | $110K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,409 | $94K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,446 | $88K |
| 82962 | <1% | 11,625 | $84K | |
| 84484 | <1% | 12,693 | $78K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,983 | $68K |
| 85027 | <1% | 9,254 | $53K | |
| 86850 | <1% | 1,995 | $53K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,283 | $53K |
| 81025 | <1% | 9,661 | $52K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 98 | $50K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,342 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,383 | $49K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,769 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 643 | $43K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,018 | $42K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,670 | $42K |
| 85610 | <1% | 13,691 | $41K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,674 | $41K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 295 | $38K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 1,652 | $37K |
| 87088 | <1% | 6,876 | $37K | |
| 81001 | <1% | 12,943 | $35K | |
| 96376 | <1% | 4,215 | $32K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 113 | $32K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 979 | $32K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,627 | $30K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,074 | $29K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,876 | $28K |
| 85730 | <1% | 5,249 | $28K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,382 | $27K |
| 84702 | <1% | 1,927 | $26K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,454 | $25K |
| 73562 | <1% | 633 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,823 | $23K |
| 83735 | <1% | 5,869 | $22K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,101 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,114 | $20K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,979 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,640 | $20K |
| 81003 | <1% | 4,100 | $19K | |
| 73630 | <1% | 336 | $19K | |
| 72131 | <1% | 415 | $18K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,978 | $17K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 447 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 156 | $17K |
| 73610 | <1% | 313 | $16K | |
| 93975 | <1% | 775 | $15K | |
| 80061 | Lipid panel | <1% | 2,192 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,881 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 404 | $14K |
| 73030 | <1% | 461 | $14K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 809 | $14K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 233 | $14K |
| 86900 | <1% | 2,280 | $13K | |
| 70498 | <1% | 44 | $13K | |
| 83880 | <1% | 2,514 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 401 | $13K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 642 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 215 | $12K |
| 99152 | <1% | 1,541 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,461 | $11K |
| 93971 | <1% | 541 | $11K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,810 | $10K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,416 | $9K |
| 99153 | Mod sedat endo service >5yrs | <1% | 998 | $9K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 43 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,060 | $8K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 47 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,535 | $7K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 280 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,765 | $7K |
| 73130 | <1% | 148 | $7K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,289 | $7K |
| C1769 | Guide wire | <1% | 507 | $7K |
| 76801 | <1% | 1,216 | $7K | |
| C1776 | Joint device (implantable) | <1% | 21 | $6K |
| 86901 | <1% | 2,407 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,861 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 153 | $6K |
| 97162 | <1% | 232 | $6K | |
| 84703 | <1% | 1,594 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 639 | $5K |
| 84100 | <1% | 2,042 | $5K | |
| 59025 | Fetal non-stress test | <1% | 162 | $5K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,574 | $5K |
| 83690 | <1% | 7,383 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,600 | $5K |
| 93017 | <1% | 246 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,823 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 230 | $4K |
| 0100U | <1% | 61 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 38 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 416 | $4K |
| 94060 | <1% | 38 | $3K | |
| 85379 | <1% | 2,379 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 856 | $3K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 72 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 151 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,930 | $3K |
| 82565 | <1% | 107 | $3K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 55 | $3K |
| 87186 | <1% | 1,905 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,402 | $2K |
| 87070 | <1% | 314 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 378 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 491 | $2K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 38 | $2K |
| 80320 | <1% | 800 | $2K | |
| 74018 | <1% | 142 | $2K | |
| 73110 | <1% | 48 | $2K | |
| 72100 | <1% | 30 | $2K | |
| 87077 | <1% | 1,245 | $2K | |
| 87205 | <1% | 337 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,112 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 417 | $2K |
| 84145 | <1% | 399 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 48 | $1K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 537 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $1K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 53 | $1K |
| 88312 | <1% | 679 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 455 | $1K |
| 83605 | <1% | 994 | $1K | |
| 87486 | <1% | 447 | $1K | |
| 87581 | <1% | 447 | $1K | |
| 90715 | <1% | 112 | $1K | |
| 87807 | <1% | 12 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 939 | $1K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 195 | $1K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 16 | $1K |
| 87040 | <1% | 629 | $977.39 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 86 | $972.79 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 850 | $970.96 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,312 | $872.57 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $870.13 |
| 72128 | <1% | 168 | $814.99 | |
| 87081 | <1% | 595 | $810.12 | |
| 88304 | <1% | 87 | $807.22 | |
| 73502 | <1% | 71 | $792.94 | |
| 93458 | <1% | 36 | $762.13 | |
| 70486 | <1% | 33 | $730.55 | |
| 82728 | <1% | 109 | $728.98 | |
| 85007 | <1% | 1,076 | $722.65 | |
| 70496 | <1% | 35 | $703.75 | |
| 87210 | <1% | 617 | $660.44 | |
| 71250 | <1% | 35 | $537.85 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 699 | $523.11 |
| 82550 | <1% | 667 | $510.43 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 55 | $493.93 |
| 83540 | <1% | 282 | $422.70 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,077 | $406.75 |
| 84132 | <1% | 84 | $403.73 | |
| 82805 | <1% | 41 | $393.91 | |
| 85652 | <1% | 149 | $348.09 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 525 | $315.24 |
| 90686 | <1% | 14 | $309.95 | |
| 88313 | <1% | 61 | $309.34 | |
| 82607 | <1% | 299 | $292.89 | |
| 00731 | <1% | 452 | $259.41 | |
| 82746 | <1% | 65 | $250.00 | |
| 00813 | <1% | 299 | $229.94 | |
| 87507 | <1% | 32 | $223.38 | |
| 83550 | <1% | 258 | $213.70 | |
| 96368 | <1% | 94 | $177.33 | |
| 51701 | <1% | 199 | $175.84 | |
| 29530 | <1% | 13 | $90.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 83 | $90.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 250 | $80.79 |
| 94729 | <1% | 85 | $65.45 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 139 | $45.69 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 14 | $40.67 |
| 86140 | <1% | 171 | $34.62 | |
| 88307 | <1% | 35 | $24.80 | |
| 82330 | <1% | 106 | $20.38 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 112 | $12.71 |
| 83615 | <1% | 46 | $2.95 | |
| 94727 | 0% | 34 | $0.00 | |
| 83970 | 0% | 114 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 13 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 380 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 38 | $0.00 |
| 00840 | 0% | 81 | $0.00 | |
| 29125 | 0% | 55 | $0.00 | |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 43 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 30 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 109 | $0.00 |
| 82248 | 0% | 15 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 23 | $0.00 |
| 96367 | 0% | 19 | $0.00 | |
| 85384 | 0% | 23 | $0.00 | |
| 84550 | 0% | 24 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 0% | 548 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 62 | $0.00 |
| 88342 | 0% | 44 | $0.00 | |
| 80329 | 0% | 70 | $0.00 | |
| 97166 | 0% | 18 | $0.00 | |
| 80069 | 0% | 91 | $0.00 | |
| 00790 | 0% | 16 | $0.00 | |
| 87147 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPENCE, BENJAMIN (CHEIF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Lee Memorial Health System | Ft Myers, FL | $97.77M |
| Lee Memorial Health System | Fort Myers, FL | $15.11M |
| Cape Memorial Hospital INC | Cape Coral, FL | $13.77M |
| Lee Memorial Health System | Fort Myers, FL | $1.60M |
| Lee Memorial Health System | Lehigh Acres, FL | $1.25M |
| Lee Memorial Health System | Fort Myers, FL | $928K |
| Access Medical South, LC | Fort Myers, FL | $856K |
| Lee Memorial Health System | Lehigh Acres, FL | $506K |
| Lee Memorial Health System | Fort Myers, FL | $333K |
| Lee Memorial Health System | North Fort Myers, FL | $192K |
| Lee Memorial Health System | Cape Coral, FL | $177K |
| Lee Memorial Health System | Fort Myers, FL | $171K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.